99 related articles for article (PubMed ID: 756468)
1. Immune complexes and diabetic microangiopathy.
Irvine WJ; Di Mario U; Guy K; Iavicoli M; Pozzilli P; Lumbroso B; Andreani D
J Clin Lab Immunol; 1978 Nov; 1(3):187-91. PubMed ID: 756468
[TBL] [Abstract][Full Text] [Related]
2. Immune complexes in newly diagnosed insulin-dependent (type I) diabetics.
Irvine WJ; Di Mario U; Guy K; Feek CM; Gray RS; Duncan LJ
J Clin Lab Immunol; 1978 Nov; 1(3):183-6. PubMed ID: 387959
[TBL] [Abstract][Full Text] [Related]
3. The correlation between insulin antibodies and circulating immune complexes in diabetics with and without microangiopathy.
Di Mario U; Ventriglia L; Iavicoli M; Guy K; Andreani D
Clin Exp Immunol; 1983 Jun; 52(3):575-80. PubMed ID: 6603299
[TBL] [Abstract][Full Text] [Related]
4. Circulating immune complexes in diabetics with severe microangiopathy: evaluation by two different methods.
Andreani D; Di Mario U; Galfo C; Ventriglia L; Iavicoli M
Acta Endocrinol (Copenh); 1982 Feb; 99(2):239-44. PubMed ID: 7036632
[TBL] [Abstract][Full Text] [Related]
5. Humoral immunity in type 1 diabetes mellitus: a prospective study.
Borsey DQ; Di Mario U; Irvine WJ; Gray RS; Guy K; Weston J; Peutherer J; Duncan LJ
J Clin Lab Immunol; 1983 May; 11(1):9-15. PubMed ID: 6876143
[TBL] [Abstract][Full Text] [Related]
6. Immune complexes in type I diabetics with persistent islet cell antibodies.
Irvine WJ; Di Mario U; Guy K; Borsey DQ
J Clin Lab Immunol; 1980 Sep; 4(2):87-9. PubMed ID: 7003148
[TBL] [Abstract][Full Text] [Related]
7. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
Savage S; Estacio RO; Jeffers B; Schrier RW
Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
[TBL] [Abstract][Full Text] [Related]
8. Increased plasma levels of IgA-IgG immune complexes and anti-F(ab')2 antibodies in patients with type 2 (non insulin-dependent) diabetes mellitus and microangiopathy.
Casiglia D; Giardina E; Scarantino G; Triolo G
Diabetes Res; 1990 Dec; 15(4):195-200. PubMed ID: 2132409
[TBL] [Abstract][Full Text] [Related]
9. New evidence of circulating immune complexes in Crohn's disease using two sensitive methods.
Pallone F; Montano S; Ricci R; Iavicoli M; Di Mario U
J Clin Lab Immunol; 1981 Jan; 5(1):23-5. PubMed ID: 7218324
[TBL] [Abstract][Full Text] [Related]
10. Development of a single numerical expression for the results of multiple screening tests for immune complexes in diabetic patients: use in statistical comparison of clinically and biochemically defined patient populations.
Kilpatrick JM; Virella G
J Clin Lab Immunol; 1982 Apr; 7(3):163-6. PubMed ID: 7047741
[TBL] [Abstract][Full Text] [Related]
11. The relationship of soluble immune complexes, insulin antibodies and insulin-anti-insulin complexes to platelet and coagulation factors in type 1 diabetic patients with and without proliferative retinopathy.
Di Mario U; Borsey DQ; Contreas G; Prowse CV; Clarke BF; Andreani D
Clin Exp Immunol; 1986 Jul; 65(1):57-65. PubMed ID: 2947762
[TBL] [Abstract][Full Text] [Related]
12. Anti-insulin antibodies and retinopathy in juvenile onset type-1 diabetes.
Sharma K; Khosla PK; Tiwari HK; Sharma RK; Bajaj JS
Indian J Ophthalmol; 1991; 39(4):174-5. PubMed ID: 1810880
[TBL] [Abstract][Full Text] [Related]
13. Impaired phagocytic function and increased immune complexes in diabetics with severe microangiopathy.
Iavicoli M; Di Mario U; Pozzilli P; Canalese J; Ventriglia L; Galfo C; Andreani D
Diabetes; 1982 Jan; 31(1):7-11. PubMed ID: 6983988
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of diabetes mellitus treated with insulin and oral hypoglycemic agents in Denmark.
Nielsen NV; Hemmingsen L
Diabetes Res; 1986 Oct; 3(8):423-5. PubMed ID: 3545623
[TBL] [Abstract][Full Text] [Related]
15. Circulating immune complexes in diabetics: the influence of sex, age, duration of disease and type of treatment.
Di Mario U; Irvine WJ; Guy K; Borsey DQ; Iavicoli M; Ventriglia L
J Clin Lab Immunol; 1983 May; 11(1):17-20. PubMed ID: 6348294
[TBL] [Abstract][Full Text] [Related]
16. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
Turk Z; Sesto M; Skodlar J; Ferencak G; Turk N; Stavljenić-Rukavina A
Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
[TBL] [Abstract][Full Text] [Related]
17. Are phospholipid-binding antibodies implicated in the pathogenesis of diabetic microangiopathy?
Giusti C
Med Hypotheses; 2004; 63(2):235-8. PubMed ID: 15236781
[TBL] [Abstract][Full Text] [Related]
18. Is diabetic microangiopathy genetically heterogeneous? HLA and diabetic nephropathy.
Barbosa J
Horm Metab Res Suppl; 1981; 11():77-80. PubMed ID: 6947952
[TBL] [Abstract][Full Text] [Related]
19. Development of diabetic microangiopathy and diabetic control. A study in non-insulin-dependent diabetics.
Maneschi F; Cassar J; Lowy C; Kohner EM
Diabete Metab; 1981 Sep; 7(3):181-7. PubMed ID: 7033009
[TBL] [Abstract][Full Text] [Related]
20. Circulating immune complexes and B lymphocytes in diabetic patients with and without microangiopathy.
Barañao RI; Tesone PA; Garberi JC; Mendelson MJ; Rumi LS
Acta Physiol Pharmacol Latinoam; 1985; 35(2):145-51. PubMed ID: 2938403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
